EP0766680A1 - Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht 4 - Google Patents

Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht 4

Info

Publication number
EP0766680A1
EP0766680A1 EP96912004A EP96912004A EP0766680A1 EP 0766680 A1 EP0766680 A1 EP 0766680A1 EP 96912004 A EP96912004 A EP 96912004A EP 96912004 A EP96912004 A EP 96912004A EP 0766680 A1 EP0766680 A1 EP 0766680A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
amino
alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96912004A
Other languages
German (de)
English (en)
Inventor
Daniele Fancelli
Carla Caccia
Dino Severino
Fabrizio Vaghi
Mario Varasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of EP0766680A1 publication Critical patent/EP0766680A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • the present invention relates to the use 'of substituted dihydrobenzofuran derivatives which act as 5-HT 4 receptor agonists in the treatment of gastrointestinal disorders and CNS disorders, to certain novel compounds having 5-HT 4 receptor agonist activity, to a process for their preparation and to pharmaceutical compositions containing them.
  • a non classical 5-hydroxytriptamine receptor has been designed (Trends Pharmacol. Sci. (1992) 13, 141-5) as the 5-HT 4 receptor.
  • 5-HT 4 receptor agonists resulted active in appropriate animal behavioural tests for memory dysfunctions (Ghelardini et al. 19 th C.I.N.P. Congress, hashington, June 1994 ; Ghelardini et al . 10 th European Society for Neurochemistry, Jerusalem, August 1994) .
  • International patent application WO 93/16072 describes 5- HT 4 receptor antagonists derived from the benzopyran, benzothiopyran or benzofuran nucleus.
  • the compounds of the invention can be useful in all the pathologies wherein a stimulation of the 5-HT 4 receptors is needed and therefore, the compounds of the invention can be useful, for example, as therapeutic prokinetic agents in the treatment of gastrointestinal disorders such as, e.g., dyspepsia, gastro-oesophageal reflux disease (GORD) and gastroparesis, and/or also in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
  • GORD gastro-oesophageal reflux disease
  • the present invention relates to dihyrobenzofuran derivatives of formula (I)
  • R lf R 2 and R 3 are, each independently, hydrogen, C ⁇ Cg alkyl, halogen, hydroxy, C j - ⁇ alkoxy, amino, C 1 -C 4 alkylamino or C ⁇ di-alkylamino;
  • X is 0, NH or CH 2 ;
  • Z is a group (a) , (b) , (c) or (d)
  • R 4 is hydrogen , C ⁇ Cg alkyl, benzyl, cyclohexylmethyl or - CH 2 -C-_ 2 -S0 2 N__-R 6 in which R 6 is C ⁇ Cg alkyl or benzyl ;
  • R 5 is Ci-Cg alkyl
  • T is halogen ; provided that, when Z is defined under (c) , then X is O or CH 2 , and their pharmaceutically acceptable salts, for use as 5-HT 4 agonists.
  • the compounds of formula (I) can therefore be useful in the treatment of all the pathologies wherein a stimulation of the 5-HT 4 receptor is needed.
  • the compounds of formula (I) may be useful as therapeutic prokinetic agents in the treatment of gastrointestinal disorders such as, for example, dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis.
  • GORD gastro-oesophageal reflux disease
  • the compounds of formula (I) may also be useful, by virtue of their 5-HT 4 agonist properties, as cognition activators, in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
  • the alkyl, alkoxy and alkylamino groups may be branched or straight groups.
  • alkyl groups include methyl, ethyl, n- and iso-propyl, n - , iso- , sec- and tert- butyl.
  • C -C. alkoxy groups include methoxy and ethoxy.
  • a C x -C 4 alkylamino group is, in particular, methylamino or ethylamino.
  • a C 1 -C 4 di-alkylamino group is, in particular, dimethylamino or diethylamino.
  • Halogen includes fluorine, bromine, chlorine or iodine, in particular, chlorine or bromine.
  • the pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts with inorganic, e.g. hydrochloric, hydrobromic, sulphuric, and phosphoric acids, or organic, e.g. acetic, propionic, lactic, oxalic, malic, maieic, tartaric, citric, benzoic, mandelic, salicylic and fumaric acids.
  • Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a) or (b) include quaternary derivatives such as, e.g., the compounds quaternised by compounds of formula R * -W wherein R- is C x - C 6 alkyl or phenyl-Ci-Cgalkyl and W is a radical corresponding to an anion of an acid.
  • R x is C--C 4 alkyl or phenyl-C 1 -C 4 alkyl, in particular it is methyl, ethyl, n-propyl, ⁇ _-butyl, benzyl or phenylethyl .
  • W is a halide such as, e.g., chloride, bromide or iodide.
  • Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a) , (b) or (c) also include internal salts, such as, e.g. N-oxides.
  • the compounds of formula (I) , their pharmaceutically acceptable salts, (including quaternary derivatives and N- oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are also object of the present invention.
  • Compounds of formula (I) wherein Z is a group (c) contain an asymmetric carbon atom and, for this reason, they can exist either as a mixture of optical isomers (racemic mixture) or as a single optical isomers (enantiomers) .
  • the enantiomers can be separately synthesised from optically pure starting material or separated from the racemic mixture in a conventional manner.
  • the present invention also include within its scope both the metabolites and the pharmaceutically acceptable bio- precursors (otherwise known as pro-drugs) of the compounds of formula (I) .
  • This invention also refers to a preferred class of compounds within formula (I), as novel compounds. These compounds, which form a further object of the invention, are compounds of formula (I)
  • R x is hydrogen
  • R 2 is chlorine or bromine; R 3 is amino; X is 0 or NH; Z is a group (a) , (b) , (c) or (d) :
  • R 4 is C 3 -C 5 alkyl or -CH 2 -CH 2 -S0 2 NH-CH 3 ;
  • R 5 is C 3 -C 3 alkyl;and T is chlorine or bromine; provided that, when Z is defined under (c) , then X is O; and their pharmaceutically acceptable salts.
  • preferred compounds according to the invention are the following: N- tl-butyl-1-azabicyclo [2, 2,2] oct-3-yl] -4-amino-5-chloro- 2 , 3 -dihydrobenzo [b] furan-7-carboxamide bromide; (1-azabicyclo [2,2,2] oct-3-yl) -4-amino-5-chloro-2, 3 -dihydro ⁇ benzo [b] furan- 7 -carboxylate; (i-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2, 3-dihydro- benzo [b] furan-7-carboxylate;
  • the compounds of formula (I) can be obtained by a process comprising : A) reacting a compound of formula (II)
  • E is OH, Cl, Br or 1-imidazolyl
  • R x , R 2 and R 3 are, each independently, hydrogen, C ⁇ Cg alkyl, halogen, hydroxy, ⁇ C- . -C 4 alkoxy, amino, C- . - ⁇ alkylamino or C- . -C 4 di-alkylamino, with an amine or an alcohol of formula (III) , (IV) or (V)
  • Q is OH or NH 2 ; n is 1,2,3 or 4; m is 0 or 1; q is 0,1 or 2; and
  • R 4 is hydrogen, Ci-Cg alkyl, benzyl, cyclohexylmethyl or
  • R 6 is C ⁇ Cg alkyl or benzyl so obtaining a compound of formula (I) wherein R l t R 2 , R 3 and R 6 are as defined above, X is NH or O and Z is a group
  • Y is OH, Cl, Br or CH 3 -NH-OCH 3
  • R-, R 2 and R 3 are are as defined above, with an organometallic derivative of formula (VII) , (VIII) or (IX)
  • M is MgBr, MgCl or Li
  • n, m, q, R 4 and R 5 are as defined above, so obtaining a compound of formula (I) wherein R x , R 2 and R 3 are as defined above, X is CH 2 and Z is a group (a) , (b) or (c) ; or C) reacting a compound of formula (X)
  • R x , R 2 , R 3 and X are as defined above, and X is NH, 0 or CH 2 , with an alkyl halide of formula R 5 T wherein R 5 is alkyl and T is halogen, so obtaining a compound of formula
  • CH 2 and Z is a group (d) ; and, if desired, when a compound of formula (I) contains an asymmetric carbon atom,
  • (II) can be reacted with an alcohol or an amine of formula (III) , (IV) or (V) in a suitable organic solvent such as, for instance, dichloromethane, tetrahydrofurane or acetonitrile, at a temperature ranging from about 0°C to about the reflux temperature of the mixture, in the presence of a proton scavenger such as, for instance, t-riethylamine, sodium hydrogen carbonate or potassium carbonate.
  • a suitable organic solvent such as, for instance, dichloromethane, tetrahydrofurane or acetonitrile
  • reaction of a compound of formula (VI) with a compound of formula (VII) , (VIII) or (IX) under step B) can also be carried out according to well known methods in the art.
  • an acyl halide of formula (VI) can be reacted with a Grignard reactive of formula (VII) , (VIII) or (IX) in a suitable organic solvent such as, e.g., tetrahydrofuran or diethyl ether in the presence of, e.g., Fe (acetylacetonate) 3 or Cul, at a temperature ranging from about -78°C to about 30°C.
  • reaction of a compound of formula (X) with an alkyl halide R 5 T under step C) can be carried out according to standard methodologies.
  • a compound of formula (X) can be reacted with a compound R 5 T as defined above, in the presence of a suitable organic solvent such as, e.g., methanol or ethanol, at a temperature ranging from about 30°C to about the reflux temperature of the mixture.
  • a suitable organic solvent such as, e.g., methanol or ethanol
  • the acid derivatives (II) and (VI) are either known products (EP 0 234 872 Al Adria Laboratories Inc. ) or may be prepared from the corresponding acids by methods well known in the art.
  • the alcohols and amines of formulae (III) , (IV) and (V) are either commercially available or known products.
  • the organometallic derivatives of formulae (VII) , (VIII) and (IX) can be prepared by standard methodologies from the corresponding alkyl halides which are either commercially available products or can be easily prepared from the corresponding alcohols of formulae (III), (IV) and (V) .
  • the compounds of formula (X) wherein X is NH are known compounds (EP 0 234 872 Al Adria Laboratories Inc.).
  • the alkyl halides of formula R S T are commercially available products.
  • the compounds of the present invention are potent agonists of 5-HT (serotonin) on 5-HT 4 receptors and can therefore be used in the treatment of the pathologies wherein a stimulation of the 5-HT 4 receptor is needed.
  • 5-HT 4 agonists are known being stimulant of gastrointestinal motility
  • the compounds of the present invention can be useful as therapeutic prokinetic agents, for example, in the treatment of gastrointestinal disease such as, for instance, dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis.
  • GORD gastro-oesophageal reflux disease
  • 5-HT 4 receptor affinity of the compounds of the present invention was determined by the inhibition of the binding of the 5-HT 4 receptor radioligand [ 3 H] -GR-113808 in rat striatum, according to the method of Grossman et al .
  • IC 50 concentration of the tested compound which forces the displacements of 50% of the bound radioligand concentration, obtained in the absence of inhibitor.
  • [L] radioligand concentration
  • Kd dissociation constant of the radioligand-receptor complex.
  • EC 50 efficacy concentration: concentration of the tested compound which induces 50% of the max. response (in this case 50% of the max. relaxation) .
  • i.a. intrinsic activity: max. response/max response of the natural agonist (in this case max. relaxation/5-HT max.relaxation) .
  • the compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscolarly, or by intravenous injection or infusion.
  • dosage forms e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscolarly, or by intravenous injection or infusion.
  • the dosage depends on the age, weight,, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration to adult humans e.g. for the representative compound of the invention FCE 29034A may range from about 1 to about 500 mg pro dose, from 1 to 5 times daily.
  • the invention includes pharmaceutical compositions comprising a compound of the invention as an active principle in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent) .
  • a pharmaceutically acceptable excipient which can be a carrier or a diluent.
  • the pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
  • the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
  • diluents e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidon
  • a starch alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
  • Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
  • the liquid dispersion for oral administration may be e.g. syrups, emulsions and suspension.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspensions or solutions for intramuscolar injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride.
  • a pharmaceutically acceptable carrier e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride.
  • the solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, acqueous, isotonic saline solutions.
  • the suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • a pharmaceutically acceptable carrier e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • Volatilies were evaporated under reduced pressure and the residue was taken up with water and ethyl acetate; the layers were separated, the organic layer was dried over anhydrous sodium sulphate and evaporated to give 1.0 of raw material, which was partially purified by column chromatography over silica gel (eluant chloroform/methyl alcohol/ammonia solution 30% 46:4:0.1) .
  • the carboxamide was conveniently isolated as its hydrochloride by adding to the free base in aceton/isopropyl alcohol 1 equivalent of hydrochloric acid in isopropyl alcohol.
  • preparation can be made of capsules having the following composition: N- (1-piperidyl)ethyl-4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxamide hydrochloride ' hydrate 50mg talc 2mg starch 2mg microcristalline cellulose 6mg magnesium stearate lmg

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à l'utilisation de dérivés de dihydrobenzofurane substitués comportant une activité d'agoniste de récepteurs 5HT4, agissant en tant qu'agents pro-cinétiques thérapeutiques dans le traitement de troubles gastro-intestinaux tels que, par exemple, la dyspepsie, la maladie du reflux gasto-÷sophagique (GORD) ou la gastro-parèsie. Les composés de l'invention peuvent être également utilisés dans le traitement des troubles SNC, caractérisés par des dysfonctionnements d'apprentissage et/ou de mémoire. Plusieurs de ces dérivés de dihydrobenzofurane sont des nouveaux composés et, en tant que tels, constituent un autre objet de l'invention ainsi que leur procédé de préparation et les compositions pharmaceutiques les contenant.
EP96912004A 1995-04-18 1996-04-04 Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht 4 Withdrawn EP0766680A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9507882.0A GB9507882D0 (en) 1995-04-18 1995-04-18 Substituted dihydrobenzofuran derivatives as 5-ht4 agonists
GB9507882 1995-04-18
PCT/EP1996/001482 WO1996033186A1 (fr) 1995-04-18 1996-04-04 Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht¿4?

Publications (1)

Publication Number Publication Date
EP0766680A1 true EP0766680A1 (fr) 1997-04-09

Family

ID=10773159

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96912004A Withdrawn EP0766680A1 (fr) 1995-04-18 1996-04-04 Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht 4

Country Status (4)

Country Link
EP (1) EP0766680A1 (fr)
JP (1) JPH10502095A (fr)
GB (1) GB9507882D0 (fr)
WO (1) WO1996033186A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
SK17212000A3 (sk) * 1998-05-14 2001-05-10 Egis Gy�Gyszergy�R Rt. Benzofuránové deriváty, farmaceutické kompozície ich obsahujúce a spôsob prípravy aktívnej zložky
TW570920B (en) 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
CN1491106A (zh) * 2001-02-05 2004-04-21 �޲��ء��߶�ķ˹�� 食管活动性功能紊乱和胃-食管反流性疾病的治疗方法
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
US6911543B2 (en) 2001-10-02 2005-06-28 Pfizer Inc. Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0307735A (pt) 2002-02-19 2005-01-25 Upjohn Co Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença
JP2005523287A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療用アザビシクロ化合物
WO2005092882A1 (fr) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
WO2013169646A1 (fr) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Procédés de maintien, de traitement ou d'amélioration de la fonction cognitive

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122528A (en) * 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
JPH0649700B2 (ja) * 1987-07-21 1994-06-29 吉富製薬株式会社 ベンゾフラン化合物
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
EP0625149A1 (fr) * 1992-02-06 1994-11-23 Smithkline Beecham Plc Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4
CA2139503A1 (fr) * 1993-05-06 1994-11-24 Christy S. John Composes pour le traitement et l'imagerie dans les cas de cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9633186A1 *

Also Published As

Publication number Publication date
WO1996033186A1 (fr) 1996-10-24
JPH10502095A (ja) 1998-02-24
GB9507882D0 (en) 1995-05-31

Similar Documents

Publication Publication Date Title
US4826838A (en) Analgesic carbocyclic and heterocyclic carbonylmethylene-and carbonylmethypipidines and-pyrrolidines
US5554627A (en) Tachykinin antagonists
EP0766680A1 (fr) Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht 4
KR100263414B1 (ko) 티에노 [3,2-b] 피리딘 유도체
CN103889981B (zh) 作为抗癌剂的三环化合物
SU1739849A3 (ru) Способ получени производных бензамида или их фармакологически приемлемых солей
NZ243993A (en) Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
SK281813B6 (sk) Tropánové deriváty, spôsob ich prípravy, použitie a farmaceutická kompozícia s ich obsahom
IL109234A (en) History of indole, their preparation and pharmaceutical preparations containing them
JPH0363280A (ja) オキサジアゾール及びその塩類、痴呆を治療するそれらの用途、それらの製造法及び処方剤
FR2696178A1 (fr) Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
EP0339950A2 (fr) Dibenzofurancarboxamides, leur utilisation comme agents pharmaceutiques, composition les contenant et procédé de préparation
EP0625149A1 (fr) Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4
CA2146923A1 (fr) Derives d'acide benzoique avec condensation heterocyclique, antagonistes du recepteur 5-ht4
EP0496064B1 (fr) Procédé de préparation de dérivés substitués de benzofuranne
FI97806C (fi) Menetelmä terapeuttisesti aktiivisten dihydrobentsofuraanikarboksamidien valmistamiseksi
RU2418794C2 (ru) ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА И БЕНЗО[h]ИЗОХИНОЛИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГИСТАМИНА H3
AU706980B2 (en) Diarylalkenylamine derivatives
JPH08502283A (ja) ５−ｈｔ▲下４▼レセプターアンタゴニスト用の縮合環系ｎ−アルキルピペリジニル−４−メチルカルボン酸エステル／アミド
CA2060965A1 (fr) Derives de la piperidine
RU2102392C1 (ru) Пиперидилметилзамещенные производные хромана и их соли с неорганическими кислотами
US5246942A (en) Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
HUT54151A (en) Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds
EA009059B1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
EP0737677A1 (fr) Dérivés de 4-indolylpipérazinyle

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE GB IT

17Q First examination report despatched

Effective date: 19980217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980630